Literature DB >> 21801625

Risk factors for death from pandemic (H1N1) 2009, southern Brazil.

Renata T C Yokota1, Lacita M Skalinski, Cristine N Igansi, Libia R O de Souza, Betine P M Iser, Priscilleyne O Reis, Eliana N C Barros, Eduardo M Macário, Marilina A Bercini, Tani M S Ranieri, Wildo N Araújo.   

Abstract

To identify risk factors for death from pandemic (H1N1) 2009, we obtained data for 157 hospitalized patients with confirmed cases of this disease. Multivariate analysis showed that diabetes and class III obesity were associated with death. These findings helped define priority vaccination groups in Brazil.

Entities:  

Mesh:

Year:  2011        PMID: 21801625      PMCID: PMC3381556          DOI: 10.3201/eid1708.101233

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


In May 2009, pandemic (H1N1) 2009 was identified in Brazil (1). In June 2009, the first confirmed death from this disease was reported in southern Brazil. On July 16, 2009, Brazil declared sustained transmission of pandemic (H1N1) 2009, and the case definition for mandatory notification was limited to suspected influenza cases with fever >38°C, cough, and dyspnea or death, i.e., severe acute respiratory infection (1). During July 19, 2009–January 2, 2010, a total of 44,544 pandemic influenza cases were confirmed and 2,051 deaths were reported in Brazil, corresponding to notification and death rates of 23.3 cases and 1.1 deaths per 100,000 population. In southern Brazil, notification and death rates reached 110 cases and 3.0 deaths per 100,000 population, and a 4.6% case-fatality rate was observed among reported patients (2). To identify risk factors for death caused by pandemic (H1N1) 2009, we analyzed data for patients hospitalized with confirmed pandemic (H1N1) 2009 at the beginning of the pandemic in southern Brazil.

The Study

This study was conducted in 11 hospitals in 4 cities (Passo Fundo, Caxias do Sul, Santa Maria, and Uruguaiana) in Rio Grande do Sul (population 10,914,128 in 2009), the southernmost state in Brazil (3). At the time of this study, these 4 cities accounted for 52% of reported deaths from pandemic (H1N1) 2009 in this state. All laboratory-confirmed (real-time reverse transcription PCR–positive) pandemic (H1N1) 2009 case-patients hospitalized in July 2009 who had shortness of breath or radiologic evidence of pneumonia and either died (case-patients) or were discharged (controls) were included. A standardized form was used that included data reported by patients who survived or their families (patients who died and patients <18 years of age) and information from medical chart review. We analyzed factors associated with death by calculating odds ratios (ORs) and 95% confidence intervals (CIs). Variables with a p value <0.10 calculated by bivariate analysis were included in a multivariate unconditional logistic regression model adjusted for age and sex. All statistical analyses were conducted by using Epi Info for Windows version 3.5.1 (Centers for Disease Control and Prevention, Atlanta, GA, USA). A p value <0.05 was considered significant. The number of confirmed pandemic (H1N1) 2009 case-patients enrolled in each city is shown in Figure 1. The study included 52 patients who died and 105 who survived (Figure 2). Characteristics and clinical findings of case-patients are shown in Table 1. A total of 136 (87%) of the 157 case-patients sought treatment before hospitalization (median 2 health care visits, range 0–5 visits). Obesity was the most frequent underlying medical condition (38%). Among obese case-patients, 19 (36%) had other risk factors for influenza complications. Diabetes was the most frequent underlying medical condition (21%) in obese case-patients. Thirty-four (49%) of 70 case-patients who did not have risk factors for influenza complications were obese (body mass index >30 kg/m2), 6 (9%) had class III obesity (body mass index >40 kg/m2), and 20 (29%) had hypertension.
Figure 1

Location of Rio Grande do Sul, Brazil (A) and distribution of 157 patients with pandemic (H1N1) 2009 in 4 cities in this state (B). Values in parentheses are numbers of patients.

Figure 2

Sample selection process for 201 patients with pandemic (H1N1) 2009, Rio Grande do Sul, Brazil, 2009.

Table 1

Characteristics of confirmed pandemic (H1N1) 2009 patients, Rio Grande do Sul, Brazil, 2009*

CharacteristicValueNo. patients
Demographic
Male sex78 (50)157
Age, y33 (0–73)157
Family income, US$678 (0–6,780)146
Education level, y†8 (0–19)129
Residence city different from hospitalization city
46 (29)
157
Smoking habits†
Current smoker34 (24)142
Years exposed to tobacco14 (1–47)33
Cigarettes/day12 (1–60)33
Pack-years8 (0–93)33
Former smoker19 (13)142
Years exposed to tobacco11 (1–54)18
Cigarettes/day20 (3–60)18
Pack-years
6.5 (0–162)
18
Signs and symptoms
Cough155 (99)157
Fever152 (97)157
Shortness of breath152 (97)157
Myalgia110 (70)157
Chills110 (70)157
Arthralgia73 (47)157
Sore throat74 (47)157
Hemoptysis18 (11)157
Diarrhea52 (33)157
Vomiting69 (44)157
Conjunctivitis9 (6)157
Headache
56 (36)
157
Seasonal influenza vaccination in the previous year‡13 (13)101
Pneumonia vaccination in the previous year‡5 (5)101
Health care treatment before hospitalization
136 (87)
157
Risk factor for influenza complication§87 (55)157
Diabetes23 (18)125
Chronic lung disease23 (18)125
Immunosuppression11 (9)125
Chronic cardiovascular disease8 (6)125
Chronic renal disease6 (5)125
Pregnancy trimester¶15 (25)59
Second5 (33)15
Third10 (67)15
Age <5 y16 (10)157
Age >60 y
7 (5)
157
Obesity#53 (38)138
Class III obesity**
10 (7)
138
Hospitalization
Admitted to intensive care unit80 (51)157
Mechanical ventilation61 (39)157
Invasive procedures69 (44)157
Clinical complications54 (34)157

*Values are no. (%) or median (range).
†Children <8 years of age were excluded from the denominator.
‡Influenza and pneumonia vaccination were checked on the vaccination card.
§Obesity was not included.
¶Percentage of pregnancy among women of reproductive age (15–49 years) was included.
#Body mass index (BMI) data were available for 138 patients. Obesity in adults was BMI >30 kg/m2; in children and adolescents <19 years of age, obesity was BMI for age >+2 z scores. Pregnant women were excluded.
**Class III obesity was BMI >40 kg/m2. Patients <19 years of age and pregnant women were excluded.

Location of Rio Grande do Sul, Brazil (A) and distribution of 157 patients with pandemic (H1N1) 2009 in 4 cities in this state (B). Values in parentheses are numbers of patients. Sample selection process for 201 patients with pandemic (H1N1) 2009, Rio Grande do Sul, Brazil, 2009. *Values are no. (%) or median (range).
†Children <8 years of age were excluded from the denominator.
‡Influenza and pneumonia vaccination were checked on the vaccination card.
§Obesity was not included.
¶Percentage of pregnancy among women of reproductive age (15–49 years) was included.
#Body mass index (BMI) data were available for 138 patients. Obesity in adults was BMI >30 kg/m2; in children and adolescents <19 years of age, obesity was BMI for age >+2 z scores. Pregnant women were excluded.
**Class III obesity was BMI >40 kg/m2. Patients <19 years of age and pregnant women were excluded. Taking medication was reported by 107 (68%) case-patients, but none received oseltamivir before hospitalization. Hospitalization occurred a median of 5 days (range 0–15 days) after symptom onset. Most case-patients (94%) received antimicrobial drugs during hospitalization, and most (81%) began antimicrobial drug therapy on the day of hospitalization. Steroids were administered to 83 (53%) case-patients a median of 1 day (range 0–11 days) after admission. Three deaths occurred during the first 24 hours of hospitalization. The case-fatality rate was higher among patients admitted to the intensive care unit (47 [59%] of 80 died). No difference was observed between patients who died and those who survived for median number of days between symptom onset and hospitalization (case-patients 6 days, range 0–6 days; controls 5 days, range 0–15 days; p = 0.25) or initiation of oseltamivir treatment (case-patients 6 days, range 1–16 days; controls 5 days, range 0–19 days; p = 0.10). After we adjusted for age and sex, diabetes (OR 4.4, 95% CI 1.5–12.8) and class III obesity (OR 6.2, 95% CI 1.3–29.2) were independently associated with death from pandemic (H1N1) 2009. No association was found between oseltamivir treatment within 48 hours of symptom onset and death (Table 2).
Table 2

Characteristics of hospitalized pandemic (H1N1) 2009 case-patients, Rio Grande do Sul, Brazil, 2009*

Characteristic
Outcome, no. (%) case-patients
Unadjusted
Adjusted†
Died
Survived
OR (95% CI)
p value
OR (95% CI)
p value
Demographic
Male sex30 (58)48 (46)1.6 (0.8–3.2)0.16NCNC
Current smoker15 (30)19 (21)1.6 (0.7–3.6)0.21NCNC
Former smoker
4 (8)
15 (18)

0.4 (0.1–1.3)
0.13

NC
NC
Underlying medical condition‡30 (58)57 (54)1.1 (0.6–2.2)0.69NCNC
Diabetes14 (27)9 (9)3.9 (1.6–9.8)0.014.4 (1.5–12.8)<0.01
Chronic lung disease9 (19)14 (18)1.1 (0.4–2.7)0.87NCNC
Immunosuppression2 (4)9 (12)0.3 (0.1–1.7)0.14NCNC
Chronic cardiovascular disease5 (11)3 (4)3.0 (0.7–13.1)0.13NCNC
Chronic renal disease1 (2)5 (6)0.3 (0.1–2.8)0.27NCNC
Pregnancy§5 (28)10 (24)1.2 (0.3–4.2)0.51NCNC
Age <5 y2 (4)14 (13)0.3 (0.1–1.2)0.06NCNC
Age >60 y
4 (8)
3 (3)

2.8 (0.6–13.2)
0.17

NC
NC
Class III obesity¶
26 (57)
27 (29)

5.3 (1.3–21.7)
<0.01

6.2 (1.3–29.2)
0.02
Oseltamivir treatment25 (48)64 (61)0.6 (0.3– 1.2)0.12NCNC
Oseltamivir <48 h after symptom onset2 (12)12 (19)0.4 (0.1–1.8)0.18NCNC
Steroid treatment32 (71)51 (57)0.5 (0.3–1.2)0.12NCNC
Antimicrobial drug treatment99 (94)49 (94)1.0 (0.2–4.1)0.99NCNC

*OR, odds ratio; CI, confidence interval; NC, not calculated.
†Adjusted for sex and age group (reference age 0–5 years).
‡Obesity excluded.
§Women of reproductive age included (15–49 years).
¶Class III obesity was a body mass index >40 kg/m2. Patients <19 years of age and pregnant women were excluded.

*OR, odds ratio; CI, confidence interval; NC, not calculated.
†Adjusted for sex and age group (reference age 0–5 years).
‡Obesity excluded.
§Women of reproductive age included (15–49 years).
¶Class III obesity was a body mass index >40 kg/m2. Patients <19 years of age and pregnant women were excluded.

Conclusions

This study confirmed findings from other countries suggesting that at the beginning of the epidemic, pandemic (H1N1) 2009 virus showed a pattern similar to that in the Northern Hemisphere. Consequently, vaccine recommendations in Brazil were made on the basis of epidemiology of pandemic (H1N1) 2009 in Brazil and other countries. Identification of diabetes and class III obesity as independent risk factors for death caused by pandemic (H1N1) 2009 among hospitalized patients in Brazil was also consistent with findings from other regions (4–8). Prevalence of obesity ranged from 26% to 74% in critically ill pandemic (H1N1) 2009 patients worldwide (5). Diabetes is also considered a risk factor for seasonal influenza complications in nonelderly persons (9). Class III obesity might increase illness and death from influenza because it impedes pulmonary function and contributes to extended mechanical ventilation and hospitalization for these patients compared with nonobese patients (10). Also, class III obesity is frequently associated with other underlying illnesses, such as cardiovascular diseases and diabetes (5). Diabetes and obesity were overrepresented among case-patients in this study compared with the general population of Rio Grande do Sul. A telephone survey conducted in Porto Alegre (capital of Rio Grande do Sul) found a 14.3% prevalence of self-reported obesity and 6.2% prevalence of self-reported diabetes in 2009 (11). Although we found a low frequency (8%) of class III obesity among patients who died, this frequency was 12.5× the estimate prevalence of class III obesity among adults in Brazil in 2003 (0.64%) (12). Our study had several limitations. Data were collected retrospectively (median 54 days, range 1–93 days after symptom onset) and by proxy interview for case-patients who died and pediatric patients and were therefore subject to recall bias. Data for analysis, including underlying illnesses and patient weight and height, were not systematically recorded in medical charts. Therefore, these data could not be used to validate questionnaire responses. Furthermore, hospitalized case-patients from whom nasopharyngeal aspirates or swab samples were not obtained were excluded from the study. Thus, the sample analyzed might not be representative of all hospitalized case-patients with severe pandemic (H1N1) 2009 during the study. However, demographic characteristics of study patients were similar to those of reported hospitalized case-patients with suspected pandemic (H1N1) 2009. Conclusions from small case series are limited, and results from this study should be considered in the context of studies in different populations. Quality of hospital care is likely to have a major role in survival rates but is difficult to compare between settings. To reduce incidence of illness and death, the Brazilian Ministry of Health obtained 110 million doses of monovalent pandemic (H1N1) vaccine for distribution in the first 3 months of 2010. Persons with chronic medical conditions, including diabetes and obesity, received priority for vaccination on the basis of international recommendations (13,14) and those of the Brazilian Ministry of Health (15). In 2010 in Brazil, >89 million persons were vaccinated against pandemic (H1N1) 2009. Our study characterized hospitalized case-patients in southern Brazil at the beginning of the pandemic. In addition, we confirmed that class III obesity and diabetes were independent risk factors for death in hospitalized case-patients with pandemic (H1N1) 2009, reinforcing the need for obtaining body mass index data for suspected case-patients during hospitalization. Furthermore, our results contributed to identification of priority groups for pandemic (H1N1) 2009 vaccination in Brazil.
  10 in total

1.  Risk factors for disease severity among hospitalised patients with 2009 pandemic influenza A (H1N1) in Spain, April - December 2009.

Authors:  P Santa-Olalla Peralta; M Cortes-García; M Vicente-Herrero; C Castrillo-Villamandos; P Arias-Bohigas; I Pachon-del Amo; M J Sierra-Moros
Journal:  Euro Surveill       Date:  2010-09-23

2.  Strategic Advisory Group of Experts on Immunization - report of the extraordinary meeting on the influenza A (H1N1) 2009 pandemic, 7 July 2009.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2009-07-24

3.  Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China.

Authors:  Hongjie Yu; Zijian Feng; Timothy M Uyeki; Qiaohong Liao; Lei Zhou; Luzhao Feng; Min Ye; Nijuan Xiang; Yang Huai; Yuan Yuan; Hui Jiang; Yingdong Zheng; Paul Gargiullo; Zhibin Peng; Yunxia Feng; Jiandong Zheng; Cuiling Xu; Yanping Zhang; Yuelong Shu; Zhancheng Gao; Weizhong Yang; Yu Wang
Journal:  Clin Infect Dis       Date:  2011-01-10       Impact factor: 9.079

4.  A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1).

Authors:  Janice K Louie; Meileen Acosta; Michael C Samuel; Robert Schechter; Duc J Vugia; Kathleen Harriman; Bela T Matyas
Journal:  Clin Infect Dis       Date:  2011-01-04       Impact factor: 9.079

5.  The association between body mass index and clinical outcomes in acute lung injury.

Authors:  Amy E Morris; Renee D Stapleton; Gordon D Rubenfeld; Leonard D Hudson; Ellen Caldwell; Kenneth P Steinberg
Journal:  Chest       Date:  2007-02       Impact factor: 9.410

6.  Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009).

Authors:  J S Nguyen-Van-Tam; P J M Openshaw; A Hashim; E M Gadd; W S Lim; M G Semple; R C Read; B L Taylor; S J Brett; J McMenamin; J E Enstone; C Armstrong; K G Nicholson
Journal:  Thorax       Date:  2010-07       Impact factor: 9.139

7.  Hospitalized adult patients with 2009 influenza A(H1N1) in Beijing, China: risk factors for hospital mortality.

Authors:  Xiuming Xi; Yuan Xu; Li Jiang; Ang Li; Jie Duan; Bin Du
Journal:  BMC Infect Dis       Date:  2010-08-27       Impact factor: 3.090

8.  Pandemic H1N1 influenza in Brazil: analysis of the first 34,506 notified cases of influenza-like illness with severe acute respiratory infection (SARI).

Authors:  Wk Oliveira; Eh Carmo; Go Penna; Rs Kuchenbecker; Hb Santos; Wn Araujo; R Malaguti; Bb Duncan; Mi Schmidt
Journal:  Euro Surveill       Date:  2009-10-22

9.  Trends in morbid obesity and in bariatric surgeries covered by the Brazilian public health system.

Authors:  Leonor Maria Pacheco Santos; Isabella Vasconcellos de Oliveira; Lilian Rose Peters; Wolney Lisboa Conde
Journal:  Obes Surg       Date:  2008-06-07       Impact factor: 4.129

10.  Impact of patient characteristics on the risk of influenza/ILI-related complications.

Authors:  D E Irwin; L B Weatherby; W Y Huang; D M Rosenberg; S F Cook; A M Walker
Journal:  BMC Health Serv Res       Date:  2001-08-21       Impact factor: 2.655

  10 in total
  13 in total

1.  Epidemiological characteristics and underlying risk factors for mortality during the autumn 2009 pandemic wave in Mexico.

Authors:  Gerardo Chowell; Santiago Echevarría-Zuno; Cécile Viboud; Lone Simonsen; Mark A Miller; Irma Fernández-Gárate; Cesar González-Bonilla; Víctor H Borja-Aburto
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

2.  Risk factors for death from Influenza A(H1N1)pdm09, State of São Paulo, Brazil, 2009.

Authors:  Ana Freitas Ribeiro; Alessandra Cristina Guedes Pellini; Beatriz Yuko Kitagawa; Daniel Marques; Geraldine Madalosso; Gerrita de Cassia Nogueira Figueira; João Fred; Ricardo Kerti Mangabeira Albernaz; Telma Regina Marques Pinto Carvalhanas; Dirce Maria Trevisan Zanetta
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

3.  Clinical aspects of influenza A(H1N1)pdm09 cases reported during the pandemic in Brazil, 2009-2010.

Authors:  Érika Valeska Rossetto; Expedito José de Albuquerque Luna
Journal:  Einstein (Sao Paulo)       Date:  2015 Apr-Jun

4.  Prevalence of Diabetes in the 2009 Influenza A (H1N1) and the Middle East Respiratory Syndrome Coronavirus: A Systematic Review and Meta-Analysis.

Authors:  Alaa Badawi; Seung Gwan Ryoo
Journal:  J Public Health Res       Date:  2016-12-21

5.  A DESCRIPTIVE STUDY OF PANDEMIC INFLUENZA A(H1N1)PDM09 IN BRAZIL, 2009 - 2010.

Authors:  Erika Valeska Rossetto; Expedito José de Albuquerque Luna
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2016-11-03       Impact factor: 1.846

6.  Influenza A(H1N1)pdm09-associated pneumonia deaths in Thailand.

Authors:  Charatdao Bunthi; Somsak Thamthitiwat; Henry C Baggett; Pasakorn Akarasewi; Ruchira Ruangchira-urai; Susan A Maloney; Kumnuan Ungchusak
Journal:  PLoS One       Date:  2013-02-04       Impact factor: 3.240

7.  Risk factors for mortality among 2009 A/H1N1 influenza hospitalizations in Maricopa County, Arizona, April 2009 to March 2010.

Authors:  G Chowell; A Ayala; V Berisha; C Viboud; M Schumacher
Journal:  Comput Math Methods Med       Date:  2012-07-15       Impact factor: 2.238

8.  Impact on pregnancies in south Brazil from the influenza A (H1N1) pandemic: cohort study.

Authors:  André Anjos da Silva; Tani Maria Schilling Ranieri; Fernanda Duarte Torres; Fernanda Sales Luiz Vianna; Graziella Rangel Paniz; Paula Baptista Sanseverino; Paulo Dornelles Picon; Pietro Baptista de Azevedo; Marta Haas Costa; Lavinia Schuler-Faccini; Maria Teresa Vieira Sanseverino
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

9.  Severe maternal morbidity due to respiratory disease and impact of 2009 H1N1 influenza A pandemic in Brazil: results from a national multicenter cross-sectional study.

Authors:  L C Pfitscher; J G Cecatti; R C Pacagnella; S M Haddad; M A Parpinelli; J P Souza; S M Quintana; F G Surita; M H Sousa; M L Costa
Journal:  BMC Infect Dis       Date:  2016-05-21       Impact factor: 3.090

10.  Influenza-like illness in an urban community of Salvador, Brazil: incidence, seasonality and risk factors.

Authors:  Carlos R Oliveira; Gisela S R Costa; Igor A D Paploski; Mariana Kikuti; Amelia M Kasper; Monaise M O Silva; Aline S Tavares; Jaqueline S Cruz; Tássia L Queiroz; Helena C A V Lima; Juan Calcagno; Mitermayer G Reis; Daniel M Weinberger; Eugene D Shapiro; Albert I Ko; Guilherme S Ribeiro
Journal:  BMC Infect Dis       Date:  2016-03-15       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.